Valproate-associated pancreatitis. Epilepsia 1993; 34: 177–183., , , , .
Weight change associated with valproate and lamotrigine monotherapy in patients with epilepsy. Neurology 2001; 56: 172–177., , , , , .
Valproic acid hepatic fatalities. III. U.S. experience since 1986. Neurology 1996; 46: 465–469., .
For the Childhood Absence Epilepsy Study Group. Ethosuximide, valproic acid, and lamotrigine in childhood absence epilepsy. New England Journal of Medicine 2010; 362: 790–799., , , , , , , , .
Efficacy of rapid IV administration of valproic acid for status epilepticus. Neurology 2005; 64: 353–355., , , , .
Epilepsy Monotherapy Trial Group. Carbamazepine versus valproate monotherapy for epilepsy: a meta-analysis. Epilepsia 2002; 43: 505–513., , , , ;
Dept. of VA Epilepsy Cooperative Study No. 264 Group. A comparison of valproate with carbamazepine for the treatment of complex partial seizures and secondarily generalized tonic-clonic seizures in adults. New England Journal of Medicine 1992; 327: 765–771., , ;
Anti-epileptic drug interactions. A clinical guide. Clarius Press: Guildford, UK; 2005..
Antiepileptic drugs – Best practice guidelines for therapeutic drug monitoring: a position paper by the Subcommission on Therapeutic Drug Monitoring, ILAE Commission on Therapeutic Strategies. Epilepsia 2008; 49: 1239–1276., , , , , , , , .
Efﬁcacy and safety of valproic acid versus phenytoin as sole therapy for newly diagnosed primary generalized tonic-clonic seizures. Journal of Epilepsy 1992; 5: 55–60., , , , .
Bioavailability of a divalproex extended-release formulation versus the conventional divalproex formulation in adult patients receiving enzyme-inducing antiepileptic drugs. Clinical Drug Investigation 2003; 23: 661–670., , , , , .
Effect of valproic acid on spike and wave discharges in patients with absence seizures. Neurology 1978; 28: 886–891., , , , , .
Antiepileptic drug pregnancy registry. Increased rate of major malformations in offspring exposed to valproate during pregnancy. Neurology 2005; 64: 961–965., , , , , .